Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
IMUNON says its Independent Data Monitoring Committee recommends continuing the Phase 2 MRD study without modification after reviewing safety data to date. It reports no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events observed so far.
IMNN - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review